The predictive value of the NMP22 bladdercheck test for bladder carcinoma in patients presenting with haematuria to a South African tertiary care centre by Purdy, Mark Richard
ABSTRACT 
 
THE PREDICTIVE VALUE OF THE NMP22 BLADDERCHEK TEST FOR 
BLADDER CARCINOMA IN PATIENTS PRESENTING WITH 
HAEMATURIA TO A SOUTH AFRICAN TERTIARY CARE CENTRE 
 
Bladder cancer is the second commonest urological malignancy and haematuria is the 
commonest symptom. Cystoscopy and urine cytology are integral for the investigation 
of haematuria, while the role of molecular markers such as the NMP22 BladderChek 
test is still being defined. The BladderChek is a qualitative point of care test 
developed for the detection of the elevated urinary levels of NMP22 associated with 
bladder cancer. No studies have been performed in South Africa using the 
BladderChek nor considered using this test to increase the efficiency of the workup of 
patients with gross haematuria. The primary aim was to establish the percentage of 
office cystoscopies done as part of a gross haematuria workup at Charlotte Maxeke 
Johannesburg Academic Hospital that are unnecessary and may be avoided if the 
BladderChek is positive under defined conditions. A cross-sectional study of the 
BladderChek test using prospective consecutive sampling, with special care to limit 
false positives and negatives, of 64 patients with a history of gross haematuria was 
conducted. The sensitivity, specificity, positive predictive value and negative 
predictive value for the BladderChek and the urine cytology were 78.9%, 84.4%, 
68.2%, 90.5% and 36.8%, 93.0%, 70.0%, 76.9% respectively. The performance of the 
BladderChek was not affected by the history of gross haematuria, the stage nor grade of 
malignancy. Urine cytology detected only one malignancy missed by the 
BladderChek. Approximately 12.6% of office cystoscopies may be avoided and 
78.9% of bladder tumours detected if the BladderChek is selectively applied as in this 
study. This may “fast-track” patients for transurethral resection of bladder tumour. 
The BladderChek may be a cost-effective alternative to urine cytology. 
 
	  
